Chad R. Haney1, Xiaobing Fan1,
Garima Agrawal1, Charles A. Pelizzari2, Gregory S.
Karczmar1, Jonathan Bakst3, Tatjana Antic3, Scott
E. Eggener4, Aytekin Oto1
1Radiology, University of
Chicago, Chicago, IL, United States; 2Radiation & Cellular
Oncology, University of Chicago, Chicago, IL, United States; 3Pathology,
University of Chicago, Chicago, IL, United States; 4Urology/Surgery,
University of Chicago, Chicago, IL, United States
Histology is the gold standard for assessing the presence or absence of cancer in prostatectomy specimen. However, the entire prostate cannot be processed and the histological processing often damages the specimen. High-resolution ex vivo MRI of the prostate can not only serve as a bridge to registering in vivo MRI with histology but can provide additional diagnostic information. We present preliminary results from 8 patients that suggests date suggest that high resolution T2-weighted ex vivo MRI differentiates between carcinoma and benign prostatic hyperplasia.